Literature DB >> 7928224

Interim results of phase II clinical testing of gadobenate dimeglumine.

G Rosati1, G Pirovano, A Spinazzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7928224     DOI： 10.1097/00004424-199406001-00060

Source DB:  PubMed          Journal:  Invest Radiol        ISSN： 0020-9996            Impact factor:   6.016


× No keyword cloud information.
  4 in total

Review 1.  Clinical experience with MultiHance in CNS imaging.

Authors:  M Essig
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

Review 2.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

3.  Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Authors:  C S Peña; S Saini; R L Baron; B A Hamm; G Morana; R Caudana; A Giovagnoni; A Villa; A Carriero; D Mathieu; M W Bourne; M A Kirchin; G Pirovano; A Spinazzi
Journal:  Korean J Radiol       Date:  2001 Oct-Dec       Impact factor: 3.500

4.  Comparison of gadobenate dimeglumine and gadopentetate dimeglumine: a study of MR imaging and inductively coupled plasma atomic emission spectroscopy in rat brain tumors.

Authors:  Tian Zhang; Akira Matsumura; Tetsuya Yamamoto; Fumiyo Yoshida; Tadao Nose; Nobuhiro Shimojo
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.